Author:
Lum Lawrence G.,Thakur Archana,Liu Qin,Deol Abhinav,Al-Kadhimi Zaid,Ayash Lois,Abidi Muneer H.,Pray Cassara,Tomaszewski Elyse N.,Steele Patricia A.,Schalk Dana L.,Yano Hiroshi,Mitchell Alice,Dufresne Melissa,Uberti Joseph P.,Ratanatharathorn Voravit
Funder
Leukemia and Lymphoma Society
National Cancer Institute
DHHS
Michigan Life Sciences
Department Oncology, Wayne State University
Subject
Transplantation,Hematology
Reference48 articles.
1. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma;Anderson;Biochem Soc Trans,1997
2. Immune consolidation with rituximab following autologous stem cell transplantation for non-Hodgkin's lymphoma: An interim report of a pilot study with historical controls;Lambert,2003
3. Interim report of an historically controlled trial of rituximab after autologous stem cell transplanation for non-Hodgkin's lymphoma;Elfenbein;Blood,2003
4. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma;Horwitz;Blood,2004
5. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma;Kamezaki;Bone Marrow Transplant,2007
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献